US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

170.79

+2.631.56%

Volume:4.30M

Turnover:732.03M

Market Cap:44.07B

PE:-12.01

High:171.04

Open:167.66

Low:167.52

Close:168.16

52wk High:176.60

52wk Low:141.05

Shares:258.02M

Float Shares:258.02M

Volume Ratio:0.56

T/O Rate:1.67%

Dividend:2.45

Dividend Rate:1.43%

EPS(TTM):-14.2170

EPS(LYR):-14.2170

ROE:-9.22%

ROA:1.03%

PB:1.28

PE(LYR):-12.01

Loading ...

Overview Company News Filings

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Analysts Are Neutral on These Real Estate Stocks: National Healthcare Properties (NHP), EPR Properties (EPR)

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)

Health Care Roundup: Market Talk

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live

Yamashita Health Care Sees FY Net Y553.00m

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity

Golden Globe Resources Sets Date and Digital Framework for 2026 AGM

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/XLV/news?page=23"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLV\",,,,,undefined,":{"symbol":"XLV","market":"US","secType":"STK","nameCN":"Health Care Select Sector SPDR Fund","latestPrice":170.79,"timestamp":1791574164779,"preClose":168.16,"halted":0,"volume":4302909,"delay":0,"changeRate":0.015639866793529945,"floatShares":258015324,"shares":258015324,"eps":-14.217021,"marketStatus":"Trading","change":2.63,"latestTime":"10-09 15:29:24 EDT","open":167.66,"high":171.035,"low":167.52,"amount":732025896.2324101,"amplitude":0.020903,"askPrice":170.8,"askSize":1251,"bidPrice":170.78,"bidSize":940,"shortable":3,"etf":1,"ttmEps":-14.217021,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":168.16,"sharesOutstanding":265215324,"nav":168.84565,"aum":43716726275.63,"dividendRate":0.014317,"bidAskSpread":0.00014,"preHourTrading":{"tag":"盘前","latestPrice":168.2,"preClose":168.16,"latestTime":"09:20 EDT","volume":1393,"amount":234322.79849999998,"timestamp":1791552029234,"change":0.04,"changeRate":0.000238,"amplitude":0.004698},"postHourTrading":{"tag":"盘后","latestPrice":168.08,"preClose":168.16,"latestTime":"19:57 EDT","volume":143283,"amount":24093637.727,"timestamp":1791503847068,"change":-0.08,"changeRate":-0.000476,"amplitude":0.001487},"volumeRatio":0.557644,"impliedVol":0.1825,"impliedVolPercentile":0.51},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLV\",,,,,undefined,":{"symbol":"XLV","floatShares":258015324,"roa":"1.03%","roe":"-9.22%","lyrEps":-14.217021,"volumeRatio":0.557644,"shares":258015324,"dividePrice":2.44525,"high":171.035,"amplitude":0.020903,"preClose":168.16,"low":167.52,"week52Low":141.05,"pbRate":"1.28","psRate":"66.90","week52High":176.595,"institutionHeld":0.7846,"latestPrice":170.79,"committee":-0.141944,"eps":-14.217021,"divideRate":0.014317,"volume":4302909,"delay":0,"ttmEps":-14.217021,"open":167.66,"prevYearClose":154.8,"prevWeekClose":166.18,"prevMonthClose":168.42,"prevQuarterClose":168.42,"fiveDayClose":166.18,"twentyDayClose":165.36,"sixtyDayClose":161.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLV\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"XLV","amount":0.642226,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-23","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-23"},{"date":"2026-06-22","symbol":"XLV","amount":0.656252,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XLV","amount":0.59468,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XLV","amount":0.656822,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XLV","amount":0.624868,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLV\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.305416,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.273839,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.307823,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.304755,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.299668,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLV\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLV\",pageSize:20,pageCount:23,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671481209","title":"Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell","url":"https://stock-news.laohu8.com/highlight/detail?id=2671481209","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671481209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:42","pubTimestamp":1790768520,"startTime":"0","endTime":"0","summary":"Moderna's eye-watering rally has officially outpaced its fundamentals, according to one analyst, prompting a downgrade at a major Wall Street firm.Citi's Geoff Meacham cut his rating on Moderna shares","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","BMED","GNOM","RXL","TRUH","XLV","IXJ","IHE","PPH","WDNA","MRNA","HRTS","MRNY","GDOC","FTXH","IDNA","FHLC","PAWZ","VHT","LGHT","IYH","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209168","title":"Analysts Are Neutral on These Real Estate Stocks: National Healthcare Properties (NHP), EPR Properties (EPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209168?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:30","pubTimestamp":1790767810,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on National Healthcare Properties (NHP) and EPR Properties (EPR) with neutral ratings, indicating that t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-these-real-estate-stocks-national-healthcare-properties-nhp-epr-properties-epr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-these-real-estate-stocks-national-healthcare-properties-nhp-epr-properties-epr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPR","NHP","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205985","title":"Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205985?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:45","pubTimestamp":1790765154,"startTime":"0","endTime":"0","summary":"Kenvue says post-hoc Phase III analysis links earlier 5% minoxidil use to higher hair regrowth in men with androgenetic alopeciaKenvue outlined new clinical and preclinical findings slated for present","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8jHf4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU0345770308.USD","FHLC","BMED","LU0787776722.HKD","KVUE","LU0289739699.SGD","XLV","IE00BVYPNV92.GBP","MEDX","LU1267930573.SGD","LU2089984988.USD","BK4592","IYH","VHT","JDOC","RXL","LU1778281490.HKD","IE00B2B36J28.USD","LU0738911758.USD","TRUH","LU2236285917.USD","SG9999001440.SGD","IE0002141913.USD","LU2471134952.CNY","LU1145028129.USD","GLAM","IE00B4R5TH58.HKD","JNJ","IXJ","LU0792757196.USD","LU1244550221.USD","LU2487616109.SGD","LU2471134796.USD","SG9999001176.USD","IHE","RSPS","PJP","GDOC","SG9999001176.SGD","BK4581","LU0689626769.HKD","LU1196500208.SGD","FTXH","LU1032955483.USD","IE000WAW04H5.SGD","LU0912757837.SGD","LU0661504455.SGD","LU1003077747.HKD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205594","title":"Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205594?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:18","pubTimestamp":1790763483,"startTime":"0","endTime":"0","summary":"An update from Marka SA ( ($PL:MRK) ) is now available. Marka S.A. has notified investors that it has executed the twelfth installment under its am...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/marka-s-a-pays-twelfth-installment-under-amended-bondholder-arrangement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/marka-s-a-pays-twelfth-installment-under-amended-bondholder-arrangement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2468319806.SGD","LU0823416689.USD","RXL","LU1699723380.USD","LU1941712264.USD","PPH","BK4585","JDOC","FHLC","LU0265550946.USD","LU0069063385.USD","IHE","SG9999015358.SGD","FTXH","LU0472753341.HKD","LU0203345920.USD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU2361045086.USD","GDOC","LU1430594728.SGD","IYH","MRK","IE00BN8TJ469.HKD","LU0070302665.USD","LU0432979614.USD","LU0868494708.USD","LU2125154778.USD","SG9999014567.USD","XLV","LU1093756168.USD","LU0058720904.USD","IE00BSNM7G36.USD","SGXZ57979304.SGD","VHT","PAWZ","LU0942090050.USD","LU0689626769.HKD","BK4559","BK4533","HRTS","TRUH","BMED","LU1162221912.USD","LU2125154935.USD","LU1989772840.SGD","LU1057294990.SGD","LU0162691827.USD","IXJ","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671082132","title":"Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2671082132","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671082132?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:05","pubTimestamp":1790762710,"startTime":"0","endTime":"0","summary":"Johnson &amp; Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/09/62072451/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","VHT","LU1983299246.USD","LU0234570918.USD","LU1221951046.USD","LU2468319806.SGD","PJP","LU0545039389.USD","LU1506573853.SGD","JNJ","IE000F7OJYX1.SGD","LU0234572021.USD","LU1043141123.HKD","FHLC","LU1585245621.USD","IE00BVYPNW00.USD","LU0345769631.USD","LU1221951129.SGD","LU0320765646.SGD","LU0511384066.AUD","LU2456880835.USD","LU1059921491.USD","BK4592","GDOC","IE00B19Z3581.USD","MEDX","LU1196500208.SGD","LU2213496289.HKD","IE0002141913.USD","IHE","LU0787776722.HKD","SG9999013999.USD","JDOC","LU0820561818.USD","IE00BJT1NW94.SGD","LU2471134523.USD","RXL","TRUH","IXJ","IYH","BK4585","LU2505996509.AUD","BMED","LU1551013342.USD","LU1929549753.HKD","SG9999001176.SGD","FTXH","LU0122379950.USD","XLV","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671089252","title":"AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2671089252","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671089252?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:55","pubTimestamp":1790762110,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1934455277.USD","LU2347655073.USD","MEDX","LU1989772923.USD","ABBV","IE0002141913.USD","LU0203345920.USD","LU0820561909.HKD","BK4533","LU1670628061.USD","LU1720051108.HKD","FTXH","AGNG","LU1037948541.HKD","PPH","IXJ","JDOC","BK4566","LU2023251221.USD","GLAM","IE00B3PB1722.GBP","TRUH","IE00B2B36J28.USD","LU2089284900.SGD","BK4550","LU1057294990.SGD","VHT","LU0058720904.USD","IYH","LU0256863811.USD","IE0000B7K699.USD","LU0029864427.USD","LU0057025933.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE000F7OJYX1.SGD","FHLC","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","PJP","IE000SO60NU8.SGD","RXL","LU2347655156.SGD","LU0472753341.HKD","LU0553294199.USD","XLV","LU0234572021.USD","LU1732800096.USD","LU0114720955.EUR","LU0395794307.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208859","title":"AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208859","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208859?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:51","pubTimestamp":1790761876,"startTime":"0","endTime":"0","summary":"AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan.Data showe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL9BGxfn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0069063385.USD","LU0912757837.SGD","LU1718418525.SGD","LU1267930490.SGD","VHT","LU1037948897.HKD","TRUH","LU0456855351.SGD","JDOC","LU1430594728.SGD","LU2357305700.SGD","LU0170899867.USD","GLAM","LU0289739343.SGD","IE00BJT1NW94.SGD","LU1037948541.HKD","AGNG","PPH","IE00BVYPNV92.GBP","LU1934455863.HKD","FHLC","LU2237443622.USD","LU0859254822.USD","LU0820561909.HKD","LU0058720904.USD","LU0310799852.SGD","LU0289961442.SGD","LU0310800379.SGD","SG9999015952.SGD","LU2125909247.SGD","LU1983299246.USD","LU2112291526.USD","LU0985320562.USD","IYH","LU1923622614.USD","LU1989772923.USD","RXL","FTXH","XLV","IXJ","LU0417517546.SGD","PJP","IE00B4R5TH58.HKD","LU0738911758.USD","LU0661504455.SGD","LU2237443978.SGD","MEDX","LU0708994859.HKD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270785","title":"Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270785?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0004445239.USD","AGNG","LU0289739343.SGD","IE000BZT7R73.USD","BK4534","LU1839511570.USD","LU0203345920.USD","LU1934455194.USD","LU0057025933.USD","PPH","GLAM","LU0198837287.USD","LU0234570918.USD","XLV","LU1093756168.USD","VHT","LU1267930490.SGD","FTXH","LU0058720904.USD","LU0820561909.HKD","TRUH","IYH","LU0395794307.EUR","LU0868494617.USD","MEDX","ABBV","IE00BJT1NW94.SGD","LU0203347892.USD","LU0417517546.SGD","LU2087621335.USD","FHLC","LU0124676726.USD","IXJ","IE00BGHQF631.EUR","PJP","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU1983299246.USD","RXL","JDOC","LU0949170772.SGD","IE0002141913.USD","LU0320765646.SGD","LU2129689431.USD","LU1244550494.USD","SG9999015952.SGD","LU1236620750.USD","LU1934455863.HKD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270207","title":"Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270207?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2347655156.SGD","PPH","LU2087621335.USD","SG9999011175.SGD","LU1732800096.USD","LU1037948897.HKD","JDOC","AGNG","MEDX","LU2237443549.SGD","LU0310800379.SGD","LU0795875169.SGD","RXL","LU0689626769.HKD","BK4139","LU1989771016.USD","LU1989772840.SGD","LU1720051017.SGD","VHT","IXJ","IE0009355771.USD","LU0158827948.USD","LU0985320562.USD","FHLC","FTXH","IE0002141913.USD","LU0545039389.USD","TRUH","LU0289739699.SGD","LU1244550577.SGD","BK4533","IE000BZT7R73.USD","IE000SO60NU8.SGD","LU2357627491.SGD","IYH","GLAM","LU1430594728.SGD","LU2089283258.USD","LU0395794307.EUR","LU0057025933.USD","LU1267930573.SGD","XLV","BK4534","IE00BLSP4239.USD","LU0128525929.USD","PJP","SG9999015978.USD","LU0943347566.SGD","ABBV","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208209","title":"AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":"BRIEF-AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month PeriodSept 30 -AbbVie Inc.ABBV.N:ABBVIE: IN PHASE 1 ABBV-295 STUDY, ALL DOSING REGIMENS RESULTED IN LS MEAN WEIGHT LOSS UP TO ABOUT 10% OVER 3-MONTH TREATMENT PERIODABBVIE: 82.2% OF ALL ABBV-295 TREATED PARTICIPANTS REPORTED MILD ADVERSE EVENTS AS HIGHEST REPORTED AE SEVERITYFurther company coverage:ABBV.N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0472753341.HKD","IE0004445239.USD","LU0310799852.SGD","PPH","LU1496350502.SGD","LU2087621335.USD","LU1732800096.USD","LU2112291526.USD","JDOC","AGNG","LU1093756168.USD","MEDX","LU2089984988.USD","LU0310800379.SGD","RXL","LU0320765646.SGD","LU1548497426.USD","LU0820561909.HKD","LU1839511570.USD","VHT","IXJ","LU0158827948.USD","LU1670627923.USD","LU0256863902.USD","IE00BN8TJ469.HKD","FHLC","FTXH","TRUH","LU0823416689.USD","LU0114720955.EUR","BK4566","IYH","LU0098860793.USD","LU0432979614.USD","LU2357305700.SGD","GLAM","LU1430594728.SGD","SG9999015952.SGD","LU0057025933.USD","LU0689472784.USD","LU1983299246.USD","XLV","LU1934455277.USD","PJP","SG9999015978.USD","LU1037948897.HKD","LU0965508806.USD","ABBV","LU1291159041.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671724342","title":"Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671724342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671724342?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:50","pubTimestamp":1790758222,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), Tectonic Therapeutic (TEC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-tectonic-therapeutic-tecx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","TECX","LU0432979614.USD","IE0009355771.USD","LU0170899867.USD","BK4581","LU0208291251.USD","LU2237957811.SGD","TMED","LU0320765489.SGD","PJP","LU1023059063.AUD","BK4137","LU2468319806.SGD","XBI","LU0868494617.USD","SG9999002232.USD","LU0058720904.USD","LU0289739699.SGD","LU1670628061.USD","IE00B2B36J28.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","XLV","IE0002141913.USD","LU1914381329.SGD","SGXZ23171101.USD","BK4568","LU1057294990.SGD","LU0128526141.USD","BK4139","LABU","SG9999004303.SGD","LU1989763690.USD","LU1721429402.USD","IHI","LU2133065610.SGD","BK4585","LU0211331839.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2112291526.USD","LU0882574055.USD","LU1721429741.USD","BK4588","HCSG","LU0266013472.USD","BK4533","LU2089984988.USD","ABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671027487","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671027487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671027487?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:20","pubTimestamp":1790756400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0749 GMT - Fresenius investors might have overreacted to news th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","PMDE","BK4581","XLV","DECU","LABU","VOTE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271707","title":"AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271707","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671271707?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:14","pubTimestamp":1790756080,"startTime":"0","endTime":"0","summary":"AbbVie's  phase 2 dose-finding study of zumilokibart in adults with moderate-to-severe atopic dermatitis met its primary endpoint, with all three dose regimens achieving \"significantly\" higher response rates at week 16, compared with placebo, the company said Wednesday.The mid-dose regimen has been selected for phase 3 development.The findings support further evaluation of the drug's efficacy, safety and extended dosing intervals as a potential long-term treatment option, AbbVie said.Atopic dermatitis is a condition that causes dry, itchy and inflamed skin.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABBV","IE00BFTCPJ56.SGD","LU1732800096.USD","LU2023251221.USD","FHLC","LU1585245621.USD","XLV","MEDX","LU1720051017.SGD","LU0069063385.USD","IYH","VHT","AGNG","JDOC","LU0456855351.SGD","LU1496350171.SGD","RXL","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","TRUH","LU1670628061.USD","LU0256863811.USD","LU0820561909.HKD","LU2357305700.SGD","LU0708994859.HKD","GLAM","IE0009355771.USD","LU0211328371.USD","BK4534","IXJ","LU0289739343.SGD","IE000SO60NU8.SGD","IE00BSNM7G36.USD","IE00BVYPNW00.USD","LU0965509101.SGD","LU0511384066.AUD","IE00BJT1NW94.SGD","PPH","BK4588","LU1983299246.USD","LU0943347566.SGD","PJP","BK4550","LU1934455863.HKD","SG9999015945.SGD","FTXH","LU0965509010.AUD","IE000WAW04H5.SGD","LU1003077747.HKD","IE00BDGV0183.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275727","title":"Yamashita Health Care Sees FY Net Y553.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671275727?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751600,"startTime":"0","endTime":"0","summary":"Yamashita Health Care Holdings Inc. also released the following forecasts:. Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4585","XBI","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220206","title":"Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:30","pubTimestamp":1790746200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUAFW3VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLAM","LU2125909247.SGD","IE0009355771.USD","MEDX","ABBV","LU0170899867.USD","LU0256863902.USD","RXL","BK4581","IXJ","LU1003077747.HKD","PJP","BK4550","FHLC","LU2125909593.SGD","LU1093756325.SGD","IYH","PPH","LU1551013425.SGD","LU1718418525.SGD","LU1929549753.HKD","XLV","JDOC","AGNG","IE0002141913.USD","LU2347655156.SGD","LU1548497426.USD","SG9999015986.USD","LU1720051017.SGD","LU0738911758.USD","VHT","LU1670627923.USD","LU1162221912.USD","IE00BSNM7G36.USD","TRUH","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0820561818.USD","LU1061106388.HKD","LU0472753341.HKD","LU0511384066.AUD","IE00BN8TJ469.HKD","LU1037948541.HKD","LU1496350171.SGD","LU0942090050.USD","LU1496350502.SGD","LU0949170772.SGD","LU2089284900.SGD","LU0708994859.HKD","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220398","title":"AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220398?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:01","pubTimestamp":1790744482,"startTime":"0","endTime":"0","summary":"AbbVie presents Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis at EADV 2026AbbVie flagged new dermatology trial and real-world results slated for presentation at the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL524zqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","IYH","LU2133065610.SGD","LU1057294990.SGD","MEDX","LU0689472784.USD","LU2089284900.SGD","LU2089283258.USD","XLV","LU1291159041.SGD","LU1585245621.USD","LU1934455277.USD","TRUH","JDOC","LU0472753341.HKD","AGNG","LU2237443382.USD","LU1923622614.USD","LU1496350171.SGD","IE00B2B36J28.USD","LU2468319806.SGD","VHT","LU0738911758.USD","PJP","LU0661504455.SGD","IE000SO60NU8.SGD","LU1074936037.SGD","LU0417517546.SGD","LU0098860793.USD","LU0289739699.SGD","LU1934455863.HKD","LU1718418525.SGD","LU0320765646.SGD","SG9999015952.SGD","FTXH","FHLC","LU0949170772.SGD","LU0795875086.SGD","GLAM","PPH","IE000F7OJYX1.SGD","LU1244550494.USD","ABBV","IXJ","LU1061106388.HKD","IE00B19Z3581.USD","LU2357627491.SGD","RXL","LU2237443895.HKD","LU2129689431.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221962","title":"IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671221962?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:11","pubTimestamp":1790734260,"startTime":"0","endTime":"0","summary":"0211 GMT - IHH Healthcare's recent share price weakness is likely an enhanced buying opportunity, with Fortis-related litigation concerns expected to have limited impact on operations, says Citi analyst Megat Fais in a note. IHH says it isn't subject to financial claims in the dispute involving Daiichi Sankyo and former Fortis promoters. IHH's India plans remain on track to reach 10,000 beds target by 2030-2031, while Singapore's recovery is expected to continue, he reckons. Malaysia should see growth from selective bed additions and medical tourism, while Turkey's strong demand and international patient flows are expected to continue, he adds. Citi keeps a buy rating and its target price at 10.40 ringgit. Shares are 0.1% higher at 7.88 ringgit.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0029874061.USD","LU0128526141.USD","BK4581","BK4137","XLV","BK4585","HCSG","DSNKY","BK4007","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671044225","title":"Golden Globe Resources Sets Date and Digital Framework for 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2671044225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671044225?lang=en_us&edition=fundamental","pubTime":"2026-09-30 08:23","pubTimestamp":1790727806,"startTime":"0","endTime":"0","summary":"Reckon Health Care Holdings Ltd ( ($AU:GGR) ) has shared an announcement. Golden Globe Resources Limited has convened its 2026 Annual General Meeti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224004","title":"Eli Lilly reports results from TRIUMPH-2 Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224004","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671224004?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:10","pubTimestamp":1790719814,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) and Company announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-reports-results-from-triumph-2-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-reports-results-from-triumph-2-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BK4W5M84.HKD","LU1064131342.USD","LU1057294990.SGD","LU0345770993.USD","LU2456880835.USD","LU0943347566.SGD","LU0354030438.USD","LU0820561909.HKD","LU0234572021.USD","SG9999018865.SGD","GDOC","LU0114720955.EUR","LU0964807845.USD","LU2023250330.USD","LU2746668974.SGD","LU2236285917.USD","LU2361045086.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU0094547139.USD","BK4007","LU0456855351.SGD","SGXZ51526630.SGD","ILDR","LU1868837300.USD","LU0672654240.SGD","LLYZ","LU0466842654.USD","LU2213496289.HKD","LU2361044949.HKD","LU0320765992.SGD","LU2746668461.USD","GB00BDT5M118.USD","LU1093756168.USD","SG9999015952.SGD","BK4581","SG9999018857.SGD","WDNA","LU2471134523.USD","LLY","LU2552382132.HKD","LU1035775433.USD","BK4534","IXJ","LU2361044865.SGD","SG9999014914.USD","LU1061106388.HKD","OZEM","LU2552382215.SGD","LU0708995401.HKD","LU1974910355.USD","IE0005OL40V9.USD","BK4533","LU0266013472.USD","LU0882574055.USD","LU2750360641.GBP","HRTS","LU2168564065.EUR","LU1989771016.USD","SG9999014880.SGD","CURE","LU1868836591.USD","LU1548497426.USD","IE00BFSS8Q28.SGD","LU0096364046.USD","LU0198837287.USD","IE00BKPKM429.USD","LU0385154629.USD","LU2063271972.USD","LU0689472784.USD","LU2089284900.SGD","IE00BN29S564.USD","XLV","LU1291159041.SGD","IE00BFSS7M15.SGD","LU0256863902.USD","AGNG","IE0001KFT4U8.USD","LU2168563687.JPY","LU2756315318.SGD","IE00B1XK9C88.USD","SG9999001176.SGD","IE00BK4W5L77.USD","ELIS","IE0004445239.USD","LU0061475181.USD","BK4588","LU1868836757.USD","LU2023251221.USD","SGXZ81514606.USD","LU0058720904.USD","TMED","LU0353189680.USD","LU2271345857.HKD","LU0225283273.USD","LU0320765059.SGD","SG9999017495.SGD","LU0432979614.USD","LU2461242641.AUD","LU2896262040.SGD","BK4599","LU1551013342.USD","LU1280957306.USD","LU0787776722.HKD","LU0353189763.USD","LU0106261372.USD","LU1629891620.HKD","LU2237438978.USD","IE00BWXC8680.SGD","LU0323591593.USD","IE00B7KXQ091.USD","LU1814569148.SGD","LU1712237335.SGD","SG9999014906.USD","IE00BJJMRY28.SGD","IYH","LU0471298694.HKD","LU2750360997.AUD","LU0823434740.USD","LU0640476718.USD","LU1127390331.HKD","LU2089283258.USD","RXL","SGXZ57979304.SGD","LU0316494557.USD","LU2168564222.USD","LU2237443622.USD","SGXZ31699556.SGD","LU2491050071.SGD","TRUH","LU0109394709.USD","LU2264538146.SGD","LU0210536198.USD","LU0354030511.USD","LU1868836914.USD","LU2089984988.USD","LU2357305700.SGD","LU2462157665.USD","CANC","LU0882574139.USD","LU1979441026.SGD","LU2211815571.USD","IE00B4JS1V06.HKD","IE0004445015.USD","LU1093756325.SGD","LLYX","IE00B775H168.HKD","IE00BKDWB100.SGD","SGXZ99366536.SGD","ELIL","LU1023059063.AUD","LU1983299246.USD","LU1623119135.USD","SG9999001176.USD","SG9999014898.SGD","LU1366192091.USD","LU0889565916.HKD","LU0158827781.USD","LU0174119429.USD","FTXH","LU1069344957.HKD","LU2112291526.USD","MEDI","SG9999013999.USD","LU2756315664.SGD","LU2111349929.HKD","LU0203201768.USD","BK4585","LU0256863811.USD","LU1232071149.USD","LU2491049909.HKD","LU0097036916.USD","LU2471134796.USD","LU0823434583.USD","PPH","LU0109391861.USD","IE00BJLML261.HKD","LU0345770308.USD","LU2237443465.HKD","LU2237443895.HKD","LU0820561818.USD","LU2237443978.SGD","LU1323610961.USD","SG9999015978.USD","IE0002141913.USD","LU2106854487.HKD","LU0823416689.USD","IHE","IE00BJJMRZ35.SGD","LU0471298777.SGD","LU2087625088.SGD","LU2168564495.EUR","MEDX","LU2028103732.USD","LU0203202063.USD","LU0683600562.USD","LLII","LU0158827948.USD","LU2491050154.USD","LU2602419157.SGD","LU1917777945.USD","LU2417539215.USD","LU1720051017.SGD","LU0820562030.AUD","LU1267930730.SGD","JDOC","IE00BJT1NW94.SGD","LU2237443382.USD","LU2265009873.SGD","THNR","LU2168564149.EUR","LU2552382058.USD","LU0122379950.USD","LU1145028129.USD","VHT","LU2237443549.SGD","PJP","LU0133085943.USD","LU0238689110.USD","LU1691799644.USD","IE00BJJMRX11.SGD","LU0417517546.SGD","LU1988902786.USD","LU0289739699.SGD","LU2324357040.USD","SG9999015945.SGD","LU1551013425.SGD","IE0009355771.USD","LU2023250504.SGD","LU2108987350.USD","LU2471134879.HKD","IE00B1BXHZ80.USD","FHLC","IE00B4R5TH58.HKD","LU0079474960.USD","LU1804176565.USD","LU1868837136.USD","LU0006306889.USD","LU2462591350.SGD","MHIP","SG9999015986.USD","LU1720051108.HKD","LU2471134952.CNY","BK4516","IE00BFTCPJ56.SGD","LU2360106947.USD","LU0786609619.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671402792","title":"Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671402792","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671402792?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:06","pubTimestamp":1790719599,"startTime":"0","endTime":"0","summary":"Lilly's experimental drug cuts weight by 21% in diabetes trialSept 29 (Reuters)-Eli LillyLLY.Nsaid on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL4N45L216:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMED","IE0004445239.USD","IE0005OL40V9.USD","SG9999014880.SGD","LU0786609619.USD","ELIL","LU1868836591.USD","ILDR","LU0058720904.USD","LU0353189680.USD","LU0787776722.HKD","LU1280957306.USD","LU1366192091.USD","LU0320765059.SGD","IE00B4R5TH58.HKD","LU2746668974.SGD","LU0466842654.USD","SGXZ31699556.SGD","LU2168564149.EUR","BK4581","LU0889565916.HKD","GDOC","LU2028103732.USD","TRUH","LU1804176565.USD","LU2237438978.USD","LU0203202063.USD","LU0174119429.USD","LU0823416689.USD","LU0289739699.SGD","IE00B775H168.HKD","LU2236285917.USD","LU2361045086.USD","IE00BJJMRY28.SGD","LU2491050071.SGD","SG9999014906.USD","BK4533","SGXZ51526630.SGD","LU1057294990.SGD","LU0882574055.USD","LU2417539215.USD","LU0471298694.HKD","LU2108987350.USD","LU2756315318.SGD","LU2089283258.USD","LU2361044949.HKD","LU2471134952.CNY","LU0689472784.USD","IE00BWXC8680.SGD","BK4516","SG9999017495.SGD","BK4534","LU2168564065.EUR","SG9999015978.USD","SGXZ99366536.SGD","LU0943347566.SGD","LU2023250504.SGD","LU1623119135.USD","SG9999001176.SGD","LU1127390331.HKD","LU1232071149.USD","LU0708995401.HKD","LU2552382215.SGD","LU1988902786.USD","LU2265009873.SGD","LU2361044865.SGD","LU2112291526.USD","LU0109394709.USD","LU0354030511.USD","LU1267930730.SGD","LU0061475181.USD","MEDX","LU0096364046.USD","LU2756315664.SGD","IE00BJJMRX11.SGD","LU0203201768.USD","IE00BJLML261.HKD","LU2746668461.USD","LU1989771016.USD","LU1548497426.USD","LU0225283273.USD","IE00B7KXQ091.USD","LU2471134523.USD","LU0079474960.USD","LU1720051017.SGD","LU2461242641.AUD","IXJ","IE0009355771.USD","LU0158827948.USD","VHT","LU0256863902.USD","FHLC","FTXH","LU0672654240.SGD","LU0097036916.USD","IE00BJT1NW94.SGD","LU2471134879.HKD","LU2360106947.USD","BK4007","LU0114720955.EUR","GB00BDT5M118.USD","LU0133085943.USD","LU0345770308.USD","LU2168564222.USD","LU2462157665.USD","LU2750360997.AUD","LU0106261372.USD","LU0266013472.USD","LU2111349929.HKD","SG9999013999.USD","LU1023059063.AUD","SG9999018865.SGD","LU2552382132.HKD","LU0234572021.USD","LU2462591350.SGD","IE00BFTCPJ56.SGD","OZEM","LU2168563687.JPY","LU2237443382.USD","SG9999014898.SGD","IE00B1BXHZ80.USD","IE00BKPKM429.USD","LU0964807845.USD","LU1093756325.SGD","LU2264538146.SGD","LU0210536198.USD","PPH","LU2023250330.USD","IHE","LU2237443465.HKD","LU1061106388.HKD","LU0823434740.USD","LU1720051108.HKD","JDOC","AGNG","IE0001KFT4U8.USD","LU2468319806.SGD","LU0683600562.USD","LU1069344957.HKD","IE00B4JS1V06.HKD","LU2089984988.USD","LU0256863811.USD","LU1868837300.USD","LU2168564495.EUR","IE00BK4W5L77.USD","SG9999014914.USD","LU0820561909.HKD","LU2491049909.HKD","LU1868836914.USD","LU2211815571.USD","LU2213496289.HKD","LU1323610961.USD","SG9999018857.SGD","SGXZ57979304.SGD","LLYZ","LU0417517546.SGD","CANC","THNR","SG9999015945.SGD","LU2023251221.USD","LU1868836757.USD","LU2271345857.HKD","LU2471134796.USD","CURE","LU1629891620.HKD","LU2602419157.SGD","BK4599","LU0323591593.USD","MEDI","LLII","LU1974910355.USD","LU1064131342.USD","LU1035775433.USD","LU1712237335.SGD","LU0823434583.USD","IYH","LU0320765992.SGD","LU0432979614.USD","IE00BKDWB100.SGD","LU2357305700.SGD","ELIS","IE00BFSS8Q28.SGD","SG9999015952.SGD","LU2087625088.SGD","LU2896262040.SGD","LU1983299246.USD","LLY","LU1814569148.SGD","LU2750360641.GBP","LU1691799644.USD","LU2237443895.HKD","WDNA","PJP","LU0122379950.USD","LU0471298777.SGD","SGXZ81514606.USD","LU1291159041.SGD","LU0385154629.USD","LU0353189763.USD","LU0456855351.SGD","LU2456880835.USD","BK4585","LU1145028129.USD","LU1868837136.USD","LU1551013425.SGD","LU1093756168.USD","LU2324357040.USD","LU2552382058.USD","LU2237443549.SGD","HRTS","IE00BFSS7M15.SGD","IE00BJJMRZ35.SGD","RXL","SG9999001176.USD","IE00B2B36J28.USD","LU1551013342.USD","LU0238689110.USD","LU2491050154.USD","BK4588","LU0109391861.USD","LU1979441026.SGD","LU0198837287.USD","LU2106854487.HKD","IE0004445015.USD","LU0006306889.USD","LU0820561818.USD","LU0820562030.AUD","IE00BN29S564.USD","LU1917777945.USD","MHIP","LU0158827781.USD","LU0640476718.USD","LU2237443978.SGD","LU0354030438.USD","LU0882574139.USD","LU2089284900.SGD","IE00B1XK9C88.USD","IE00BK4W5M84.HKD","XLV","LU0316494557.USD","LLYX","LU2237443622.USD","SG9999015986.USD","LU2063271972.USD","LU0345770993.USD","LU0094547139.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":31,"pageCount":23,"totalSize":617,"code":"91000000","status":"200"}]}}